Probiodrug News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.08.19	DGAP-News: Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update (EQS Group)
22.08.19	DGAP-News: Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019 (EQS Group)
22.08.19	DGAP-AFR: Vivoryon Therapeutics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] (EQS Group)
22.08.19	DGAP-AFR: Vivoryon Therapeutics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäss § 114, 115, 117 WpHG (EQS Group)
09.07.19	Vivoryon Therapeutics (PBD-NA): Agreement with MOR in I-O, earlier than expected (EQS Group)
08.07.19	DGAP-News: Vivoryon Therapeutics AG: MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology (EQS Group)
18.06.19	DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology (EQS Group)
15.06.19	Vivoryon Therapeutics (PBD-NA): Fresh funding for AD. Immuno-oncology optionality explored (EQS Group)
12.06.19	DGAP-News: Aus Probiodrug AG wird Vivoryon Therapeutics AG (EQS Group)
12.06.19	DGAP-News: Probiodrug AG becomes Vivoryon Therapeutics AG (EQS Group)
29.05.19	DGAP-News: Probiodrug AG: Ordinary General Meeting of Shareholders of Probiodrug AG (EQS Group)
22.05.19	Probiodrug to attend International Conferences in June 2019 (EQS Group)
16.05.19	DGAP-News: Probiodrug AG: Probiodrug Reports First Quarter 2019 Business Update (EQS Group)
09.05.19	DGAP-News: Probiodrug AG: Probiodrug AG to Publish its First Quarter 2019 Business Update on May 16, 2019 (EQS Group)
18.04.19	DGAP-News: Probiodrug AG: Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 29 May 2019 (EQS Group)
15.04.19	DGAP-DD: Probiodrug AG deutsch (EQS Group)
15.04.19	DGAP-DD: Probiodrug AG deutsch (EQS Group)
15.04.19	DGAP-News: Probiodrug AG: Probiodrug raises EUR 8.2 million in successful private placement of new shares (EQS Group)
09.04.19	DGAP-News: Probiodrug AG: Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares (EQS Group)
04.04.19	DGAP-News: Probiodrug AG: Probiodrug AG has mandated ODDO SEYDLER BANK AG as Designated Sponsor (EQS Group)
28.03.19	DGAP-News: Probiodrug AG: Probiodrug reports full year 2018 financial results (EQS Group)
21.03.19	DGAP-News: Probiodrug AG: Probiodrug AG to Publish its Full Year 2018 Results on March 28, 2019 (EQS Group)
21.03.19	DGAP-AFR: Probiodrug AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] (EQS Group)
21.03.19	DGAP-AFR: Probiodrug AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäss § 114, 115, 117 WpHG (EQS Group)
20.03.19	DGAP-News: Probiodrug AG: Probiodrug and Alzheimer's Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912 (EQS Group)
12.03.19	Probiodrug to attend BIO Europe Spring in March 2019 (EQS Group)
05.02.19	Probiodrug AG: Probiodrug to attend International Conferences in February 2019 (EQS Group)
18.12.18	DGAP-News: Probiodrug to attend J.P. Morgan Healthcare Conference in January 2019 (EQS Group)
29.11.18	DGAP-News: Probiodrug Reports Third Quarter 2018 Business Update (EQS Group)
29.11.18	DGAP-News: Probiodrug veröffentlicht Quartalsbericht für das dritte Quartal 2018 (EQS Group)
01.11.18	Edison Investment Research Limited: Edison issues outlook on Probiodrug (PBD) (EQS Group)
16.10.18	DGAP-News: Probiodrug veröffentlicht Daten der SAPHIR-Studie in einer Peer-Review-Publikation (EQS Group)
15.10.18	Probiodrug AG: Loss announcement a non-event (EQS Group)
04.09.18	DGAP-News: Probiodrug ernennt Dr. Michael Schaeffer zum Executive Vice President Business & Strategy (EQS Group)
03.09.18	Probiodrug (PBD-NA): Phase IIb trial prep for PQ912 in AD continues: (EQS Group)
30.08.18	DGAP-News: Probiodrug berichtet Finanzergebnisse für das erste Halbjahr 2018 und Unternehmens-Update (EQS Group)
23.08.18	DGAP-AFR: Probiodrug AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] (EQS Group)
23.08.18	DGAP-AFR: Probiodrug AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäss § 114, 115, 117 WpHG (EQS Group)
13.07.18	DGAP-DD: Probiodrug AG english (EQS Group)
13.07.18	DGAP-DD: Probiodrug AG deutsch (EQS Group)
13.07.18	Probiodrug (PBD-NA): Positive read-across from BAN2401 Phase II data (EQS Group)
12.07.18	DGAP-DD: Probiodrug AG deutsch (EQS Group)
12.07.18	DGAP-DD: Probiodrug AG english (EQS Group)
23.05.18	DGAP-DD: Probiodrug AG deutsch (EQS Group)
23.05.18	DGAP-DD: Probiodrug AG english (EQS Group)
23.05.18	DGAP-DD: Probiodrug AG english (EQS Group)
23.05.18	DGAP-DD: Probiodrug AG deutsch (EQS Group)
27.03.18	DGAP-Vorabbekanntmachung: Probiodrug AG (EQS Group)
27.03.18	DGAP-Vorabbekanntmachung: Probiodrug AG (EQS Group)
29.08.17	Press Release: Unique binding mode of PBD-C06 to pGlu-Abeta peptides identified (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Holcim	91.22	1.56 %	K V
Sonova Hldg	319.70	1.56 %	K V
Lonza Grp	591.00	1.34 %	K V
Sika	231.50	1.27 %	K V
CieFinRichemont	171.70	0.94 %	K V
Swiss Re	138.05	-0.40 %	K V
Zurich Insur Gr	537.20	-0.52 %	K V
Kuehne+Nagel Int	204.60	-0.97 %	K V
Part Grp Hldg	1’389.50	-1.03 %	K V
Givaudan	3’818.00	-3.12 %	K V

Nachrichten zu Probiodrug AG

Aktien Top/Flop

Meistgelesene Nachrichten